Pharma Equity Group A/S Cl A
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022… Read more
Pharma Equity Group A/S Cl A (PEG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.136x
Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) has a cash flow conversion efficiency ratio of -0.136x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-6.66 Million) by net assets (Dkr48.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharma Equity Group A/S Cl A - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Pharma Equity Group A/S Cl A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pharma Equity Group A/S Cl A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharma Equity Group A/S Cl A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
2invest AG
XETRA:2INV
|
N/A |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3
|
0.122x |
|
Hercules Investments Limited
NSE:HERCULES
|
-0.001x |
|
Carbonxt Group Ltd
AU:CG1
|
-0.146x |
|
Plus Group Holdings Inc.
F:EJ0
|
N/A |
|
Chin Huay PCL
BK:CH
|
0.040x |
|
Steel Hawk Berhad
KLSE:0320
|
N/A |
|
Bayview Acquisition Corp Class A Ordinary Shares
NASDAQ:BAYA
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Pharma Equity Group A/S Cl A (2009–2024)
The table below shows the annual cash flow conversion efficiency of Pharma Equity Group A/S Cl A from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | Dkr48.88 Million | Dkr-22.86 Million | -0.468x | +28.72% |
| 2023-09-30 | Dkr25.33 Million | Dkr-16.62 Million | -0.656x | -951.34% |
| 2022-09-30 | Dkr46.05 Million | Dkr-2.87 Million | -0.062x | -27.18% |
| 2021-09-30 | Dkr42.57 Million | Dkr-2.09 Million | -0.049x | +83.01% |
| 2020-09-30 | Dkr34.28 Million | Dkr-9.90 Million | -0.289x | -6981.66% |
| 2019-09-30 | Dkr67.16 Million | Dkr-274.00K | -0.004x | +79.96% |
| 2018-09-30 | Dkr77.57 Million | Dkr-1.58 Million | -0.020x | +64.80% |
| 2017-09-30 | Dkr85.09 Million | Dkr-4.92 Million | -0.058x | -2992.17% |
| 2016-09-30 | Dkr96.78 Million | Dkr-181.00K | -0.002x | +93.66% |
| 2015-09-30 | Dkr99.53 Million | Dkr-2.94 Million | -0.030x | +39.77% |
| 2014-09-30 | Dkr97.95 Million | Dkr-4.80 Million | -0.049x | -189.26% |
| 2013-09-30 | Dkr-105.44 Million | Dkr-5.79 Million | 0.055x | +118.92% |
| 2012-09-30 | Dkr36.39 Million | Dkr-10.56 Million | -0.290x | -304.66% |
| 2011-09-30 | Dkr79.67 Million | Dkr-5.71 Million | -0.072x | +78.56% |
| 2010-09-30 | Dkr53.06 Million | Dkr-17.75 Million | -0.334x | -2303.51% |
| 2009-09-30 | Dkr53.47 Million | Dkr-744.00K | -0.014x | -- |